Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
However, the outlook for earnings is robust, with forecasts calling for 66.89% annual earnings growth and a transition to profitability within the next three years. This figure is well above market averages. Revenue is also expected to rise at an impressive 22.7% per year, outpacing the typical 10.3% seen across the US market. Shares are currently trading at $35.16, a notable discount to the estimated fair value of $131.42. While recent share price volatility introduces some risk, the combination of rapid anticipated profit growth and strong value signals gives investors plenty to consider this earnings season. See our full analysis for Travere Therapeutics. The next section puts these headline numbers in context, comparing them to the most widely followed narratives about the company to see which stories hold up and which may be challenged. See what the community is saying about Travere Therapeutics NasdaqGM:TVTX Earnings & Revenue History as at Nov 2025 Margins Projected t
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]Seeking Alpha
- Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TVTX's page on the SEC website